A137310 Stock Overview
An in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
SD Biosensor, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩9,850.00 |
| 52 Week High | ₩16,210.00 |
| 52 Week Low | ₩9,570.00 |
| Beta | 1.1 |
| 11 Month Change | -1.99% |
| 3 Month Change | -16.53% |
| 1 Year Change | -19.46% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -83.85% |
Recent News & Updates
Shareholder Returns
| A137310 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -1.7% | -0.7% | -1.0% |
| 1Y | -19.5% | 11.1% | 7.4% |
Return vs Industry: A137310 underperformed the KR Medical Equipment industry which returned 11.1% over the past year.
Return vs Market: A137310 underperformed the KR Market which returned 7.4% over the past year.
Price Volatility
| A137310 volatility | |
|---|---|
| A137310 Average Weekly Movement | 4.8% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A137310's share price has been volatile over the past 3 months.
Volatility Over Time: A137310's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 576 | Hyo Keun Lee | www.sdbiosensor.com |
SD Biosensor, Inc, an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company’s products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters.
SD Biosensor, Inc Fundamentals Summary
| A137310 fundamental statistics | |
|---|---|
| Market cap | ₩1.21t |
| Earnings (TTM) | -₩256.18b |
| Revenue (TTM) | ₩649.67b |
1.9x
P/S Ratio-4.7x
P/E RatioIs A137310 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A137310 income statement (TTM) | |
|---|---|
| Revenue | ₩649.67b |
| Cost of Revenue | ₩417.21b |
| Gross Profit | ₩232.46b |
| Other Expenses | ₩488.64b |
| Earnings | -₩256.18b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.09k |
| Gross Margin | 35.78% |
| Net Profit Margin | -39.43% |
| Debt/Equity Ratio | 17.2% |
How did A137310 perform over the long term?
See historical performance and comparison